Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 46, Issue 5, 2007, Pages 566-572

  Greenhill, Laurence L ^a   Newcorn, Jeffrey H ^b   Gao, Haitao ^c   Feldman, Peter D ^c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Adverse event; Atomoxetine; Attention deficit hyperactivity disorder; Titration

Indexed keywords

ATOMOXETINE; PLACEBO;

ADOLESCENT; ARTHRALGIA; ARTICLE; CHILD; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SINUS CONGESTION; SOMNOLENCE; SORE THROAT; STOMACH DISCOMFORT; TREATMENT DURATION; UPPER ABDOMINAL PAIN; VOMITING;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PROPYLAMINES; SEVERITY OF ILLNESS INDEX;

EID: 34247381694     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/chi.0b013e3180335ad1     Document Type: Article

References (18)

1. Bogetto F, Albert U, Maina G (2002), Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 12:181-186
2. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998), ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: Guilford
3. Feifel D, Moutier CY, Perry W (2000), Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry 61:909-911
4. Heil SH, Holmes HW, Bickel WK et al. (2002), Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67:149-156
5. Hirschfeld RM, Allen MH, McEvoy JP, Keck PE Jr, Russell JM (1999), Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 60:815-818
6. Hsu PH, Laddu AR (1994), Analysis of adverse events in a dose titration study. J Clin Pharmacol 34:136-141
7. Kaufman J, Birmaher B, Brent D, Rao U, Ryan N (1996), Kiddie-SADS-Present and Lifetime Version (K-SADS-PL). Pittsburgh: University of Pittsburgh Press
8. Kelsey DK, Sumner CR, Casat CD et al. (2004), Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114:e1-e8
9. Kimko HC, Cross JT, Abernethy DR (1999), Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 37:457-470
10. Kratochvil CJ, Wernicke J, Schuh K, Zhang S, Faries D, Kelsey D (2002), Long-term safety of atomoxetine in children treated for ADHD. Scientific Proceedings of the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, May
11. Meador KJ (1998), Cognitive and behavioral assessments in antiepileptic drug trials. In: Antiepileptic Drug Development, French J, Dichter M, Leppik I, eds. Philadelphia: Lippincott-Raven, pp 231-238
12. Michelson D, Allen AJ, Busner J et al. (2002), Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901
13. Physician's Desk Reference (2005), Physician's Desk Reference. Montvale, NJ: Thomson Healthcare
14. SAS Institute (1997), SAS/STAT Software: Changes and Enhancements Through Release 6.12. Cary, NC: SAS Institute
15. Spencer T, Heiligenstein JH, Biederman J et al. (2002), Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140-1147
16. Sramek JJ, Kirkesseli S, Paccaly-Moulin A et al.(1998), A bridging study of fananserin in schizophrenic patients. Psychopharmacol Bull 34:811-818
17. Toth P, Frankenburg FR (1994), Clozapine and seizures: a review. Can J Psychiatry 39:236-238
18. Weisler RH (2005), Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD. Expert Opin Pharmacother 6:1003-1018